Recursion Pharmaceuticals
clinical rescued phenotypic defects of cells with knockdown compared to thousands of other molecules tested rescued phenotypic defects substantially better including better rescue than other inhibitors for specific knockdown findings validated in tumor cell lines and grown from human epithelial tumor cells with mutation more selectivity in tumor cell lines with mutation inhibited growth and organization of insight loss | Recursion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
108 of 143
Related slides by other companies
SentiBio
SPAC
October 2021
armed car cells exhibit significantly improved killing of cancer cells a in tumor cell day post culture ratio i | SentiBio
Mink Therapeutics
Investor Day
November 2022
car enhances infiltration of tumor specific cells to clear tumor mink | Mink Therapeutics
Immatics
Investor Presentation
November 2023
format is designed for optimized efficacy and safety | Immatics
Matinas BioPharma
Investor Presentation
January 2024
in tumor cell inhibition with formulations rationale and next steps | Matinas BioPharma
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io